A Study to Evaluate the Safety, Tolerability and Immunogenicity of V114 in Healthy Adults and Infants (V114-005)



Status:Recruiting
Conditions:Pneumonia, Infectious Disease
Therapuetic Areas:Immunology / Infectious Diseases, Pulmonary / Respiratory Diseases
Healthy:No
Age Range:Any - 49
Updated:3/12/2016
Start Date:September 2015
End Date:August 2017
Contact:Toll Free Number
Phone:1-888-577-8839

Use our guide to learn which trials are right for you!

A Phase I-II, Randomized, Double-Blind, Study to Evaluate the Safety, Tolerability, and Immunogenicity of Different Formulations of V114 in Healthy Adults and Infants

This study is designed to assess the effect of different dose levels of pneumococcal
polysaccharide and adjuvant on the safety and immunogenicity of V114 in healthy adults and
infants.


Inclusion Criteria:

Adult Cohort: 18 to 49 years and in good health

- Highly unlikely to conceive from vaccination through 6 weeks after administration of
the study vaccine.

Infant Cohort: approximately 2 months (42 to 90 days) and in good health.

Exclusion Criteria:

Adult cohort: Prior administration of any pneumococcal vaccine

- History of invasive pneumococcal disease

- Known hypersensitivity to any vaccine component

- Known or suspected impairment of immune function

- Coagulation disorder contraindicating intramuscular vaccination

- Received a blood transfusion or blood products within 6 months

- Participated in another clinical study of an investigational product within 2 months

- Breast feeding. Infant cohort: Prior administration of any pneumococcal vaccine

- Known hypersensitivity to any vaccine component

- Known or suspected impairment of immune function

- History of congenital or acquired immunodeficiency

- Has or mother has documented Human Immunodeficiency virus (HIV) infection

- Has or mother has documented hepatitis B surface antigen positive result

- Functional or anatomic asplenia

- History of failure to thrive

- Coagulation disorder contraindicating intramuscular vaccination

- History of autoimmune disease or autoimmune disorder

- Known neurologic or cognitive behavioral disorder

- Received systemic corticosteroids within 14 days

- Received other licensed non-live vaccine within 14 days

- Received other licensed live virus vaccine within 30 days

- Received a blood transfusion or blood products

- Participated in another clinical study of an investigational product

- History of invasive pneumococcal disease
We found this trial at
18
sites
?
mi
from
Galveston, TX
Click here to add this to my saved trials
?
mi
from
Bardstown, KY
Click here to add this to my saved trials
?
mi
from
Bellevue, NE
Click here to add this to my saved trials
?
mi
from
Birmingham, AL
Click here to add this to my saved trials
?
mi
from
Charlottesville, VA
Click here to add this to my saved trials
?
mi
from
Cleveland, OH
Click here to add this to my saved trials
?
mi
from
Dayton, OH
Click here to add this to my saved trials
East Norriton, Pennsylvania 19401
?
mi
from
East Norriton, PA
Click here to add this to my saved trials
?
mi
from
East Syracuse, NY
Click here to add this to my saved trials
?
mi
from
Haughton, LA
Click here to add this to my saved trials
?
mi
from
Hermitage, PA
Click here to add this to my saved trials
?
mi
from
Jonesboro, AR
Click here to add this to my saved trials
?
mi
from
Lebanon, TN
Click here to add this to my saved trials
?
mi
from
Murray, UT
Click here to add this to my saved trials
?
mi
from
Philadelphia, PA
Click here to add this to my saved trials
?
mi
from
San Antonio, TX
Click here to add this to my saved trials
?
mi
from
San Diego, CA
Click here to add this to my saved trials
?
mi
from
Sioux Falls, SD
Click here to add this to my saved trials